NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAVUDINE; LAMIVUDINE is a fixed-dose combination oral tablet containing two nucleoside reverse transcriptase inhibitors (NRTIs) used in antiretroviral therapy. This combination targets HIV by inhibiting viral reverse transcriptase enzyme activity. The product is in pre-launch stage under sponsor PharmaIN.
PRE_LAUNCH
Pre-launch stage indicates early-phase commercial buildout; team expansion likely imminent as regulatory pathway progresses.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STAVUDINE; LAMIVUDINE offers exposure to HIV market dynamics and pre-launch commercial development within a sponsor organization (PharmaIN). Career growth depends on successful regulatory approval and market entry execution.
Brand ManagerRegulatory Affairs Specialist
Worked on STAVUDINE; LAMIVUDINE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.